



Xenon to Present at Upcoming Investor Conferences

April 15, 2026

VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the second quarter of 2026.

- **Bloom Burton & Co. Healthcare Investor Conference**, Toronto, Ontario
Company Presentation: Wednesday, April 22, 2026, 11:30 am–12:00 pm ET
- **Bank of America Global Healthcare Conference**, Las Vegas, NV
Company Presentation: Thursday, May 14, 2026, 8:00–8:30 am PT (11:00–11:30 am ET)
- **RBC Capital Markets Global Healthcare Conference**, New York, NY
Company Presentation: Tuesday, May 19, 2026, 9:30–9:55 am ET
- **Jefferies Global Healthcare Conference**, New York, NY
Company Presentation: Thursday, June 4, 2026, 9:55–10:25 am ET

Details about all company presentations, including webcast information, can be found on the [Investors](#) section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_v7 and Na_v1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on [LinkedIn](#) and [X](#).

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.

Contacts:

For Investors:

Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com

For Media:

Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com



Source: Xenon Pharmaceuticals Inc.